#### FORM D

Notice of Exempt Offering of Securities

1 Issuer's Identity

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C.

OMB APPROVAL
OMB Number: 3235-0076
Expires: August 31, 2015
Estimated Average burden hours per response: 4.0

Entity Type

C Other

• Corporation

C Limited Partnership

C General Partnership C Business Trust

C Limited Liability Company

1. 1550Cl 5 10Cl lity	
CIK (Filer ID Number)	Previous Name(s) 🔲 None
0000109657	DDI
Name of Issuer	PHARMACEUTICALS
OXIS INTERNATIONAL INC	DIAGNOSTIC DATA
Jurisdiction of Incorporation/Organization	INC /DE/
DELAWARE	
Year of Incorporation/Organizati	- on
Over Five Years Ago	
C Within Last Five Years (Specify Year)	

• Yet to Be Formed

## 2. Principal Place of Business and Contact Information

Name of Issuer			
OXIS INTERNATIONAL INC			
Street Address 1		Street Address 2	
4830 W KENNEDY BLVD		SUITE 600	
City	State/Province/Country	y ZIP/Postal Code	Phone No. of Issuer
ТАМРА	FLORIDA	33609	(310) 860-5184

## 3. Related Persons

Last Name	First Name		Middle Name
			Iviiddie Name
Cataldo	Anthony		
Street Address 1		Street Address 2	
4830 West Kennedy Blvd		Suite 600	
City	State/Province/O	Country	ZIP/Postal Code
Tampa	FLORIDA		33609
Relationship: Exec	cutive Officer	Director	Promoter
Clarification of Response (if Necess	ary)		
·			
Last Name	First Name		Middle Name
Weldon	Steven		
Street Address 1		Street Address 2	
4830 West Kennedy Blvd		Suite 600	
City	State/Province/O	Country	ZIP/Postal Code

Tampa		FLORIDA			33609	)	
Relationship:	Executiv	ve Officer	•	Director		Promoter	
Clarification of Response (if Necessary)							

## 4. Industry Group

## C Agriculture

## Banking & Financial Services

- Commercial Banking
- **C** Insurance
- C Investing
- C Investment Banking
- C Pooled Investment Fund

Other Banking & Financial C Services

#### C Business Services

#### Energy

- C Coal Mining
- C Electric Utilities
- C Energy Conservation
- C Environmental Services
- C Oil & Gas
- C Other Energy

#### Health Care Biotechnology

- C Health Insurance
- C Hospitals & Physicians
- C Pharmaceuticals
- **O** Other Health Care
- C Manufacturing

## Real Estate

- C Commercial
- C Construction
- C REITS & Finance
- C Residential
- C Other Real Estate

#### <sup>C</sup> Retailing

#### C Restaurants

#### Technology

- C Computers
- C Telecommunications
- O Other Technology

#### Travel

- C Airlines & Airports
- C Lodging & Conventions
- C Tourism & Travel Services
- C Other Travel

#### O Other

## 5. Issuer Size

No Revenues

\$1 - \$1,000,000

\$1,000,001 - \$5,000,000

\$5,000,001 - \$25,000,000

Over \$100,000,000

**Decline to Disclose** 

Not Applicable

\$25,000,001 - \$100,000,000

## **Revenue Range**

C

•

C

C

000

C

C

#### Aggregate Net Asset Value Range

- C No Aggregate Net Asset Value
- C \$1 \$5,000,000
- C \$5,000,001 \$25,000,000
- © \$25,000,001 \$50,000,000
- C \$50,000,001 \$100,000,000
- Over \$100,000,000
- C Decline to Disclose
  - Not Applicable

# 6. Federal Exemption(s) and Exclusion(s) Claimed (select all that apply)

0

Rule 504(b)(1) (not (i), (ii) or (iii))		Rule 505						
Rule 504 (b)(1)(i)		Rule 506(b)						
Rule 504 (b)(1)(ii)		Rule 506(c)						
Rule 504 (b)(1)(iii)		Securities Act Section 4	(a)(5)					
		Investment Company Act Section 3(c)						

7. Type of F	iling		
New Notice	Date of First Sale	2015-07-09	First Sale Yet to Occur
Amendment			
8. Duration	of Offering		
Does the Issuer inter	nd this offering to last n	nore than one year?	C Yes © No

9.	. Type(s) of Securities Offered (select all that apply)						
	Pooled Investment Fund Interests	•	Equity				
Γ	Tenant-in-Common Securities	•	Debt				
	Mineral Property Securities	Γ	Option, Warrant or Other Right to Acquire Another Security				
	Security to be Acquired Upon Exercise of Option, Warrant or Other Right to Acquire Security		Other (describe)				

## 10. Business Combination Transaction

Is this offering being made in connection with a business combination transaction, such as a merger, acquisition or exchange offer?

Clarification of Response (if Necessary)

## 11. Minimum Investment

Minimum investment accepted from any outside \$ 1000

12. Sales Compensation	
Recipient	Recipient CRD Number 🔲 None
(Associated) Broker or Dealer 📃 None	(Associated) Broker or Dealer CRD 🔲 None
Street Address 1	Street Address 2
City State	/Province/Country ZIP/Postal Code
State(s) of Solicitation	All States

USD

# 13. Offering and Sales Amounts

<b>Total Offering Amount</b>	\$ 1500000	USD	🗖 Indefinite
Total Amount Sold	\$ 500000	USD	
Total Remaining to be Sold	\$ 1000000	USD	Indefinite

## 14. Investors

Select if securities in the offering have been or may be sold to persons who do not qualify as accredited investors, Number of such non-accredited investors who already have invested in the

2

rumber	or such	non-acci	cuittu	1117030013	** 110 6	ancauy	maye my	cottu m	une
offering									

Regardless of whether securities in the offering have been or may be sold to persons who do not qualify as accredited investors, enter the total number of investors who already have invested in the offering:

15. Sales Commissions & Finders' Fees Expenses

Provide separately the amounts of sales commissions and finders' fees expenses, if any. If the amount of an expenditure is not known, provide an estimate and check the box next to the amount.

Sales Commissions	\$	USD	Estimate	
Finders' Fees	\$	USD	<b>Estimate</b>	
Clarification of Response (if Necessary)				

## 16. Use of Proceeds

Provide the amount of the gross proceeds of the offering that has been or is proposed to be used for payments to any of the persons required to be named as executive officers, directors or promoters in response to Item 3 above. If the amount is unknown, provide an estimate and check the box next to the amount.

\$	300000	USD	Estimate
Clarification of Response (if Necessary)			
Signature and Submission			

Please verify the information you have entered and review the Terms of Submission below before signing and clicking SUBMIT below to file this notice.

#### **Terms of Submission**

In submitting this notice, each Issuer named above is:

- Notifying the SEC and/or each State in which this notice is filed of the offering of securities described and undertaking to furnish them, upon written request, the information furnished to offerees.
- Irrevocably appointing each of the Secretary of the SEC and, the Securities Administrator or other legally designated officer of the State in which the Issuer maintains its principal place of business and any State in which this notice is filed, as its agents for service of process, and agreeing that these persons may accept service on its behalf, of any notice, process or pleading, and further agreeing that such service may be made by registered or certified mail, in any Federal or state action, administrative proceeding, or arbitration brought against it in any place subject to the jurisdiction of the United States, if the action, proceeding or arbitration (a) arises out of any activity in connection with the offering of securities that is the subject of this notice, and (b) is founded, directly or indirectly, upon the provisions of: (i) the Securities Act of 1933, the Securities Exchange Act of 1934, the Trust Indenture Act of 1939, the Investment Company Act of 1940, or the Investment Advisers Act of 1940, or any rule or regulation under any of these statutes, or (ii) the laws of the State in which the issuer maintains its principal place of business or any State in which this notice is filed.
- Certifying that, if the issuer is claiming a Regulation D exemption for the offering, the issuer is not disqualified from relying on Regulation D for one of the reasons stated in Rule 505(b)(2)(iii) or Rule 506(d).

Each Issuer identified above has read this notice, knows the contents to be true, and has duly caused this

notice to be signed on its behalf by the undersigned duly authorized person.

For signature, type in the signer's name or other letters or characters adopted or authorized as the signer's signature.

Issuer	Signature	Name of Signer	Title	Date
OXIS INTERNATIONAL INC	/s/ Steven Weldon	Steven Weldon	Chief Financial Officer	2015-07-24